• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

呋塞米总体反应的决定因素:药代动力学和药效学。

Determinants of the overall response to furosemide: pharmacokinetics and pharmacodynamics.

作者信息

Brater D C

出版信息

Fed Proc. 1983 Apr;42(6):1711-3.

PMID:6832391
Abstract

After an oral or i.v. dose of furosemide, there is considerable interindividual variability in the amount of unchanged drug delivered into the urine. On the average, approximately half as much reaches the intraluminal site of action with an oral compared with an i.v. dose. However, the natriuretic response to the same dose administered by either route is virtually the same. Similarly, after pretreatment with probenecid, the same total amount of furosemide in urine causes a greater overall response. It has been presumed that this paradox is accounted for by differences in rate of delivery of furosemide to the active site such that after an oral dose or after pretreatment with probenecid, amounts of drug are at the "steep" portion of the dose-response curve for longer periods of time. Our analysis shows that this is not the case. For furosemide, the amount of diuretic delivered into the urine that is maximally efficient (21.5 micrograms/min) is considerably less than the amount causing half-maximal response (69.8 micrograms/min). Oral administration or pretreatment with probenecid maintains drug close to this maximally efficient amount more persistently than does i.v. administration. By so doing, total response to an oral dose approaches that of i.v. dosing despite delivering half the amount of drug to the active site, and after probenecid an i.v. dose causes a greater response than i.v. dosing alone despite delivering the same amount of drug to the active site. These data emphasize the importance of the time course of delivery of drug to the active site as an independent determinant of overall response.

摘要

口服或静脉注射呋塞米后,进入尿液的原形药物量存在相当大的个体间差异。平均而言,口服给药时到达管腔内作用部位的药物量约为静脉注射剂量的一半。然而,两种给药途径给予相同剂量时的利钠反应实际上是相同的。同样,在使用丙磺舒预处理后,尿液中相同总量的呋塞米会引起更大的总体反应。据推测,这种矛盾现象是由于呋塞米向活性部位的递送速率不同所致,即口服给药后或用丙磺舒预处理后,药物量在剂量-反应曲线的“陡峭”部分持续更长时间。我们的分析表明情况并非如此。对于呋塞米,产生最大利尿效率(21.5微克/分钟)时进入尿液的利尿药量远低于产生半数最大反应(69.8微克/分钟)时的药量。口服给药或用丙磺舒预处理比静脉注射给药更持久地使药物维持在接近最大利尿效率的药量水平。这样一来,尽管口服给药时到达活性部位的药量仅为静脉注射给药的一半,但其总体反应接近静脉注射给药;而在使用丙磺舒后,静脉注射给药尽管到达活性部位的药量相同,但却比单独静脉注射给药产生更大的反应。这些数据强调了药物向活性部位递送的时间过程作为总体反应的一个独立决定因素的重要性。

相似文献

1
Determinants of the overall response to furosemide: pharmacokinetics and pharmacodynamics.呋塞米总体反应的决定因素:药代动力学和药效学。
Fed Proc. 1983 Apr;42(6):1711-3.
2
The time course of delivery of furosemide into urine: an independent determinant of overall response.呋塞米在尿液中排泄的时间过程:总体反应的一个独立决定因素。
Kidney Int. 1982 Jul;22(1):69-74. doi: 10.1038/ki.1982.134.
3
Pharmacokinetic-dynamic analysis of the indomethacin-furosemide interaction in man.吲哚美辛与速尿在人体中的药代动力学-药效学分析。
J Pharmacol Exp Ther. 1980 Oct;215(1):77-81.
4
Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration.多次静脉给药后呋塞米耐受性的药效学建模
Clin Pharmacol Ther. 1996 Jul;60(1):75-88. doi: 10.1016/S0009-9236(96)90170-8.
5
Effect of water deprivation for 48 hours on the pharmacokinetics and pharmacodynamics of azosemide in rats.
Res Commun Mol Pathol Pharmacol. 1996 Jul;93(1):109-28.
6
Influence of probenecid and spironolactone on furosemide kinetics and dynamics in man.丙磺舒和螺内酯对呋塞米在人体中的动力学和药效学的影响。
Clin Pharmacol Ther. 1977 Oct;22(4):402-9. doi: 10.1002/cpt1977224402.
7
Pharmacokinetics and pharmacodynamics of furosemide after direct administration into the stomach or duodenum.呋塞米直接注入胃或十二指肠后的药代动力学和药效学
Biopharm Drug Dispos. 1997 Dec;18(9):753-67. doi: 10.1002/(sici)1099-081x(199712)18:9<753::aid-bdd63>3.0.co;2-k.
8
Assessment of diuretic effects and changes in plasma aldosterone concentration following oral administration of a single dose of furosemide or azosemide in healthy dogs.对健康犬单次口服速尿或阿佐塞米后利尿作用及血浆醛固酮浓度变化的评估。
Am J Vet Res. 2008 Dec;69(12):1664-9. doi: 10.2460/ajvr.69.12.1664.
9
Role of binding in distribution of furosemide: where is nonrenal clearance?呋塞米分布中结合的作用:非肾清除在哪里?
Fed Proc. 1983 Apr;42(6):1699-702.
10
Preliminary evaluation of furosemide-probenecid interaction in humans.速尿-丙磺舒在人体中的相互作用的初步评估。
J Pharm Sci. 1980 May;69(5):571-5. doi: 10.1002/jps.2600690526.

引用本文的文献

1
Furosemide use in Italian neonatal intensive care units: a national survey.呋塞米在意大利新生儿重症监护病房的使用:一项全国性调查。
Ital J Pediatr. 2020 Jun 22;46(1):86. doi: 10.1186/s13052-020-00851-2.
2
Clinical pharmacology of furosemide in neonates: a review.新生儿呋塞米的临床药理学:综述。
Pharmaceuticals (Basel). 2013 Sep 5;6(9):1094-129. doi: 10.3390/ph6091094.
3
Clinical pharmacology of the loop diuretics furosemide and bumetanide in neonates and infants.袢利尿剂呋塞米和布美他尼在新生儿和婴儿中的临床药理学。
Paediatr Drugs. 2012 Aug 1;14(4):233-46. doi: 10.2165/11596620-000000000-00000.
4
Furosemide dynamics in conscious rabbits: modulation by angiotensin II.清醒家兔中呋塞米的动力学:血管紧张素II的调节作用
Cardiovasc Drugs Ther. 1995 Apr;9(2):311-7. doi: 10.1007/BF00878676.
5
Clinical pharmacokinetic considerations in the treatment of increased intracranial pressure.颅内压升高治疗中的临床药代动力学考量
Clin Pharmacokinet. 1987 Jul;13(1):1-25. doi: 10.2165/00003088-198713010-00001.
6
Analysis of the natriuretic action of a loop diuretic, piretanide, in man.速尿剂吡咯他尼对人体利钠作用的分析。
Br J Clin Pharmacol. 1991 Apr;31(4):463-9. doi: 10.1111/j.1365-2125.1991.tb05563.x.